Login / Signup
Safety and feasibility of toripalimab plus lenvatinib with or without radiotherapy in advanced BTC.
Yunchao Wang
Nan Zhang
Jingnan Xue
Chengpei Zhu
Yanyu Wang
Longhao Zhang
Xu Yang
Hao Wang
Shanshan Wang
Jiashuo Chao
Xiaobo Yang
Haitao Zhao
Published in:
Frontiers in immunology (2023)
The addition of RT may enhance the efficacy of toripalimab plus lenvatinib. Toripalimab plus lenvatinib with RT have a good safety profile without an increase in specific toxicities in advanced BTC patients.
Keyphrases
</>
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
early stage
radiation therapy
prognostic factors
peritoneal dialysis
locally advanced
rectal cancer